CLOs on the Move

Motus GI

www.motusgi.com

 
Motus GI Holdings, Inc. (NASDAQ: MOTS) is a medical technology company based in the U.S., with subsidiaries in the U.S. and Israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. The Company is focused on the development and commercialization of the Pure-Vu® System, designed to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.motusgi.com
  • 1301 E. Broward Blvd. Suite 310
    Fort Lauderdale, FL USA 33301
  • Phone: 954.541.8000

Executives

Name Title Contact Details

Similar Companies

Integrated Medical

Integrated Medical, Inc. is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Franz Center For Children

Franz Center For Children is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mededge Inc

Mededge Inc is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Owlet Baby Care

The world`s first infant health tracker, designed to notify you if your baby`s heart rate or oxygen levels fall out of range. Rest assured with Owlet.

Motif Neurotech

Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.